Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes with Progressive Supranuclear Palsy-like Manifestations

• Published in: Brain sciences Vol. 14; no. 10; p. 1012
• Main Authors: Yamahara, Naoki, Takekoshi, Akira, Kimura, Akio, Shimohata, Takayoshi
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09.10.2024; MDPI
• Subjects: Akinesia; Antibodies; Ataxia; Atrophy; Autoimmune diseases; autoimmune encephalitis; Cancer therapies; Care and treatment; Case reports; Diagnosis; Disease; Encephalitis; Gait; Immunity (Disease); Immunoblotting; Immunotherapy; paraneoplastic neurological syndrome; Pathology; Patients; Progressive supranuclear palsy; Proteins; Review; Steroids; Testicular cancer; Tumors; Viral antibodies; autoimmune encephalitis; paraneoplastic neurological syndrome; progressive supranuclear palsy
• ISSN: 2076-3425; 2076-3425
• DOI: 10.3390/brainsci14101012

Advances in diagnostic procedures have led to an increasing rate of diagnosis of autoimmune encephalitis or paraneoplastic neurological syndrome (AE/PNS) among patients with progressive supranuclear palsy (PSP)-like manifestations. In this narrative review, we first discuss the clinical characteristics of AE/PNS in comparison to those of PSP, followed by a discussion of diagnosis and treatment. The antibodies involved in these conditions include anti-IgLON5, -Ma2, and -Ri antibodies, each of which has a characteristic clinical presentation. The steps in the diagnosis of AE/PNS in patients with PSP-like manifestations include (i) suspicion of AE/PNS based on clinical presentations atypical of PSP and (ii) antibody detection measures. Methods used to identify antibodies include a combination of tissue-based assays and confirmatory tests. The primary confirmatory tests include cell-based assays and immunoblotting. Treatments can be divided into immunotherapy and tumor therapies, the former of which includes acute and maintenance therapies. One of the major challenges of diagnosis is that existing reports on PSP-like patients with AE/PNS include only case reports, with the majority discussing antibodies other than anti-IgLON5 antibody. As such, more patients need to be evaluated to establish the relationship between antibodies and PSP-like manifestations.